Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.08.08.21261766: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding The experiments were performed in blind regarding to the allocation groups. Power Analysis Statistical analysis: No statistical methods were used to predetermine sample size. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Secondary end points were the proportion of patients with positive anti-SARS-CoV-2 antibodies (define as an antibody binding unit (BU) above 1.1 for IgG and 0.2 for IgA) at M1 and M3, T-cell response defined by the number of circulating SARS-CoV-2-spike-specific IFNγ-producing T cells at M1 and M3, breakthrough infections and safety. anti-SARS-CoV-2sugges…SciScore for 10.1101/2021.08.08.21261766: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding The experiments were performed in blind regarding to the allocation groups. Power Analysis Statistical analysis: No statistical methods were used to predetermine sample size. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Secondary end points were the proportion of patients with positive anti-SARS-CoV-2 antibodies (define as an antibody binding unit (BU) above 1.1 for IgG and 0.2 for IgA) at M1 and M3, T-cell response defined by the number of circulating SARS-CoV-2-spike-specific IFNγ-producing T cells at M1 and M3, breakthrough infections and safety. anti-SARS-CoV-2suggested: (PhosphoSolutions Cat# CoV2-2G1, RRID:AB_2868397)M3suggested: NoneThis assay is highly sensitive and allows quantification of antibodies through a standardized MFI (referred as Binding Unit; BU), which is calculated using an anti-spike monoclonal antibody as reference. anti-spikesuggested: NoneExperimental Models: Cell Lines Sentences Resources S-Flow assay: The S-Flow assay was used to detect antibodies bound to 293T cells stably expressing the spike protein (S) at their surface using flow cytometry. 293Tsuggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)The variant strains were isolated from nasal swabs using Vero E6 cells and amplified by two passages. Vero E6suggested: RRID:CVCL_XD71)Software and Algorithms Sentences Resources Flow cytometry data were analyzed with FlowJo v. FlowJosuggested: (FlowJo, RRID:SCR_008520)Statistical analyses were conducted using GraphPad Prism 9. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. The findings are observational and based on small numbers and should be interpreted with caution. Differences in treatment groups where highly associated with the type of underlying inflammatory disease, and there may be differences among the populations. However, except for more frequent renal involvement at diagnosis in the “rituximab” group and younger age in the “cDMARDs” group, patients’ characteristics were comparable between treatment groups. Overall, we found that rituximab and methotrexate differentially impact the immunogenicicty of BNT162b2 vaccine, by imparing B-cell and T-cell responses, respectively. The Delta variant fully escapes the sub-optimal humoral response of individuals treated with rituximab. Our findings support efforts to improve effectiveness of mRNA vaccines in this immunocompromised population.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04870411 Recruiting Immunological Response to COVID-19 Vaccine in Patients With … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 27. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
